High Dose IV Vitamin C Therapy
Cancer cells, unlike healthy human cells are both flawed and primeval.
Cancer cells are lacking in many enzymes that normal healthy cells have in copiousness amounts and also, they are not able to use oxygen to metabolize glucose into energy production. One example of a particular enzyme that transforms oxygen and water in hydrogen peroxide is catalase.
Hydrogen peroxide production in and outside the cells results from high doses of vitamin c (ascorbic acid). Hydrogen peroxide is used by normal cells for specific metabolic needs and whatever is not needed is converted in oxygen and water which is healthy stuff.
Here’s the good news, cancer cells have very small amounts of catalase, so they aren’t able to convert the hydrogen peroxide into water and oxygen and as a result, they are oxidized and killed off. So, what does this tell us, well, it tells us that ascorbic acid or vitamin c is very good for healthy cells and very bad for cancer cells.
The National Institute of Health (NIH), the National Cancer Institute (NCI) and the Food and Drug Administration (FDA) have finally confirmed the research findings that Linus Pauling, PhD, Hugh Riordan, MD and many other scientists and physicians over the past few decades have conducted regarding the therapeutic utility of treating cancer with vitamin C.
The NIH study confirms in vitro, the hypotheses described by Riordan et al in “Intravenous Ascorbate as a Chemotherapeutic and Biologic Response Modifying Agent”:
- Tumor cells are more susceptible to the effects of high-dose, ascorbate-induced peroxidation products because of a relative catalase deficiency.
- Concentrations of ascorbate high enough to kill tumor cells can be achieved in humans.
Neil H. Riordan PhD. commented on the study, “It is gratifying to have our research on vitamin C and cancer confirmed by scientists at the prestigious National Institutes of Health.”
High Dose Vitamin C Therapy
Listed below are several, peer reviewed references regarding vitamin C as it pertains to the treatment of cancer.
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissues
Qi Chen *, Michael Graham Espey, Murali C. Krishna, James B. Mitchell, Christopher P. Corpe *, Garry R. Buettner, Emily Shacter, and Mark Levine * Reference Link
*Molecular and Clinical Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892; Radiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892; Free Radical and Radiation Biology Program, University of Iowa, Iowa City, IA 52242-1101; and Laboratory of Biochemistry, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892 PNAS | September 20, 2005 | vol. 102 | no. 38 | 13604-13609
Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 Years Later
By Michael J. González, Jorge R. Miranda-Massari, Edna M. Mora, Angelik Guzmán, Neil H. Riordan, Hugh D. Riordan, Joseph J. Casciari, James A. Jackson, and Angel Romá-Franco, from Integrative Cancer Therapies 4(1); 2005 pp.32-44
Intravenous Ascorbic Acid: Protocol for its Application and Use
By Hugh D. Riordan, Ronald E. Hunninghake, Neil H. Riordan, James A. Jackson, Xiao LongMeng, Paul Taylor, etal, from Puerto Rico Health Sciences Journal (2003) 22:3, 287-290
The Effect of Alternating Magnetic Field Exposure and Vitamin C on Cancer Cells
By N. Mikirova, J.A. Jackson, J.P. Casciari and H.D. Riordan, from Journal of Orthomolecular Medicine (2001) 3, 177-182
Cytotoxicity of Ascorbate, Lipoic Acid, and Other Antioxidants In Hollow Fibre In Vitro Tumours
By J.P. Casciari, N.H. Riordan, T.L. Schmidt, XL Meng, J.A. Jackson and H.D. Riordan, from British Journal of Cancer (2001) 84:11, 1544-1550
Clinical and Experimental Experiences with Intravenous Vitamin C
By N.H. Riordan, H.D. Riordan, J.A. Jackson and J.P. Casciari, from Journal of Orthomolecular Medicine (2000) 15:4, 201-213
Different Fatty Acid Composition Between Normal and Malignant Cell Lines
By X.L. Meng, N.H. Riordan, H.D. Riordan, J.A. Jackson, et al, from BioMedicina, (1999) 2:4, 5-7
Rethinking Vitamin C and Cancer: An Update on Nutritional Oncology
By M.J. Gonzalez, E. Mora, N.H. Riordan, H.D. Riordan and P. Mojica, from Cancer Prevention International (1998) 3, 215-224
Intravenous Ascorbate as a Chemotherapeutic and Biologic Response Modifying Agent
Bio-Communications Research Institute (1997)
Intravenous Vitamin C in a Terminal Cancer Patient
By N.H. Riordan, J.A. Jackson and H.D. Riordan, from Journal of Orthomolecular Medicine (1996) 11, 80-82
High-Dose Intravenous Vitamin C and Long-Time Survival of a Patient with Cancer of Head of the Pancreas
By J.A. Jackson, H.D. Riordan, R.E. Hunninghake and N.H. Riordan, from Journal of Orthomolecular Medicine (1995) 10, 87-88
Intravenous Ascorbate as a Tumor Cytotoxic Chemotherapeutic Agent
By N.H. Riordan, H.D. Riordan, X. Meng, Y. Li and J.A. Jackson, from Medical Hypotheses (1995) 44, 207-213
Case Study: High-Dose Intravenous Vitamin C in the Treatment of a Patient withAdenocarcinoma of the Kidney
By H.D. Riordan, J.A. Jackson and Mavis Schultz, from Journal of Orthomolecular Medicine (1990) 5:1, 5-7